The takeaway
Aurinia Pharmaceuticals Inc shows a slight seasonal lean over 10 years of data — strongest in March (+11.6%) and softest in December (+13.8%).
Right now
In July, the stock has risen 50% of years, averaging +2.1% — essentially in line with the S&P 500.
The full picture
Aurinia Pharmaceuticals Inc's most dependable month has been March, higher in 6 of 10 years; December has been its least reliable, up just 30% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in December (+12.8 pts); it has trailed the market most in February (−4.3 pts).
“vs S&P” is Aurinia Pharmaceuticals Inc’s average for a month minus the S&P 500’s average for that same month — isolating Aurinia Pharmaceuticals Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, March has closed higher 60% of the time versus 60% across the last 10 years — the pattern is holding.
Figures are the typical (median) March return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
This is a feast-or-famine calendar. March reads as the strong month, higher in 6 of 10 Marches, but the tale is one of a few outsized years more than steady gains.
Read it with one caveat: the average (+11.6%) runs well ahead of the median (+1.4%), so a handful of outsized years — not steady strength — do much of the lifting. That reliability comes with real swings, mind — even March ranges by 33.1% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — March has outpaced the S&P 500 by +10.6 points on average.
March anchors a run, too: the March-through-May window has been the stock's reliable season. At the other end of the calendar, December is the year's low point, though even there the stock has stayed positive on average (+13.8%), a sign every month leans up, and the edge isn't year-round — the stock has trailed the S&P 500 in February, August, and April. Its roughest month on record was a −46.1% August in 2016 — a reminder of how hard even a seasonal name can fall.
Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
Hold it loosely, then: the March tendency is genuine but lumpy, more about the occasional outsized year than a gain to bank on. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (March), its worst (December), and whether it really trades seasonally.
Only mildly. The stock's months are fairly even — March is the firmest (+11.6%) and December the softest (+13.8%), a narrow spread that points to weak seasonality rather than a strong calendar effect.
March has been the strongest, averaging +11.6% and closing higher in 6 of 10 years since 2016.
It's the weakest month, but it has still averaged a small gain (+13.8%) — quiet rather than genuinely bad.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade